Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 16, Number 7—July 2010

Dispatch

Postexposure Treatment of Marburg Virus Infection

Thomas W. GeisbertComments to Author , Lisa E. Hensley, Joan B. Geisbert, Anders Leung, Joshua C. Johnson, Allen Grolla, and Heinz Feldmann
Author affiliations: National Emerging Infectious Diseases Laboratories Institute, Boston, Massachusetts, USA (T.W. Geisbert, J.B. Geisbert); US Army Medical Research Institute of Infectious Diseases, Fort Detrick, Maryland, USA (L.E. Hensley, J.C. Johnson); Public Health Agency of Canada, Winnipeg, Manitoba, Canada (A. Leung, A. Grolla); National Institutes of Health, Hamilton, Montana, USA (H. Feldmann)

Main Article

Table 2

Serologic response profiles of Marburg virus–infected rhesus monkeys after treatment with VSVΔG/Marburg virus glycoprotein vectors*

Animal no. Group Treatment Time of treatment after challenge, h Serum anti–Marburg virus IgG†
Day 6 Day 10 Day 14
1 Exp 1 VSV-Marburg 24 0 320 1,000
2 Exp 1 VSV-Marburg 24 0 100 1,000
3 Exp 1 VSV-Marburg 24 0 0 NA
4 Exp 1 VSV-Marburg 24 0 100 320
5 Exp 1 VSV-Marburg 24 0 1,000 1,000
6 Exp 1 VSV-Marburg 24 0 320 320
Control 1 Cont 1 VSV-Lassa 24 0 0 NA
7 Exp 2 VSV-Marburg 48 0 320 1,000
8 Exp 2 VSV-Marburg 48 0 0 NA
9 Exp 2 VSV-Marburg 48 0 0 NA
10 Exp 2 VSV-Marburg 48 0 320 1,000
11 Exp 2 VSV-Marburg 48 0 0 NA
12 Exp 2 VSV-Marburg 48 0 0 NA
Control 2 Cont 2 VSV-Lassa 48 0 0 NA
Control 3 Cont 3 None NT 0 0 NA

*VSV, vesicular stomatitis virus; Ig, immunoglobulin; Exp, experimental group; Cont, control group; NA, not applicable because animal had died; NT, not treated.
†Endpoint dilution titers.

Main Article

TOP